Electrocore (NASDAQ:ECOR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday.

According to Zacks, “Electrocore, LLC operates as a bio-electronic medicine company. It reseraches and develops therapeutic technologies based in neurology and rheumatology. Electrocore, LLC is based in NJ, United States. “

Other equities analysts have also issued reports about the company. Cantor Fitzgerald began coverage on Electrocore in a report on Friday, September 21st. They issued an “overweight” rating for the company. BTIG Research reissued a “buy” rating on shares of Electrocore in a report on Thursday, November 15th.

Shares of NASDAQ:ECOR traded down $0.46 during trading on Thursday, hitting $5.38. 164,273 shares of the company traded hands, compared to its average volume of 297,250. Electrocore has a one year low of $4.16 and a one year high of $20.25.

Electrocore (NASDAQ:ECOR) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.45). The business had revenue of $0.15 million during the quarter. Equities research analysts anticipate that Electrocore will post -1.13 EPS for the current year.

In other news, CEO Francis R. Amato bought 7,500 shares of the business’s stock in a transaction on Thursday, December 6th. The stock was purchased at an average cost of $6.53 per share, for a total transaction of $48,975.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Peter S. Staats bought 10,000 shares of the business’s stock in a transaction on Thursday, December 13th. The stock was purchased at an average price of $4.83 per share, with a total value of $48,300.00. The disclosure for this purchase can be found here. Insiders purchased a total of 24,800 shares of company stock valued at $146,842 over the last three months.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brown Brothers Harriman & Co. acquired a new stake in Electrocore in the third quarter worth approximately $140,000. Point72 Asset Management L.P. acquired a new stake in Electrocore in the second quarter worth approximately $206,000. SCP Investment LP acquired a new stake in Electrocore in the third quarter worth approximately $260,000. Bfsg LLC acquired a new stake in Electrocore in the third quarter worth approximately $301,000. Finally, Citadel Advisors LLC acquired a new stake in Electrocore in the second quarter worth approximately $427,000. Hedge funds and other institutional investors own 16.31% of the company’s stock.

About Electrocore

electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Recommended Story: Depreciation

Get a free copy of the Zacks research report on Electrocore (ECOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Electrocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electrocore and related companies with MarketBeat.com's FREE daily email newsletter.